MISTMilestone Pharmaceuticals Inc.

Nasdaq milestonepharma.com


$ 1.72 $ 0.02 (1.18 %)    

Monday, 13-May-2024 13:59:54 EDT
QQQ $ 442.79 $ -0.62 (-0.14 %)
DIA $ 394.68 $ -1.70 (-0.43 %)
SPY $ 520.84 $ -1.77 (-0.34 %)
TLT $ 90.43 $ 0.10 (0.11 %)
GLD $ 216.22 $ -0.96 (-0.44 %)
$ 1.7
$ 1.70
$ 1.69 x 200
$ 1.72 x 300
$ 1.70 - $ 1.72
$ 1.33 - $ 4.49
36,354
na
90.54M
$ 0.40
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-29-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-24-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-29-2021 12-31-2020 10-K
15 11-13-2020 09-30-2020 10-Q
16 08-12-2020 06-30-2020 10-Q
17 05-14-2020 03-31-2020 10-Q
18 03-06-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-13-2019 06-30-2019 10-Q
21 06-19-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 milestone-pharmaceuticals-to-present-data-on-etripamil-at-the-preventative-cardiovascular-nursing-symposium

Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of i...

 milestone-pharmaceuticals-announces-etripamil-data-demonstrating-patients-ability-to-self-manage-recurring-psvt-presented-at-the-american-college-of-cardiology-annual-meeting

Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of i...

 milestone-pharmaceuticals-to-present-data-on-etripamil-at-the-american-college-of-cardiology-and-european-heart-rhythm-association-annual-conferences

Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of i...

 hc-wainwright--co-reiterates-buy-on-milestone-pharmaceuticals-maintains-25-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains...

 milestone-pharmaceuticals-q4-gaap-eps-032-misses-031-estimate-cash-balance-of-66m-expected-to-provide-cash-runway-into-2026

aMilestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.32) per share which missed the analyst consensus esti...

 piper-sandler-maintains-overweight-on-milestone-pharmaceuticals-lowers-price-target-to-5

Piper Sandler analyst Edward Tenthoff maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and lowers the pri...

 why-butterfly-network-shares-are-trading-lower-by-22-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed four...

 why-okta-shares-are-trading-higher-by-around-24-here-are-20-stocks-moving-premarket

Shares of Okta, Inc. (NASDAQ: OKTA) shares rose sharply in today’s pre-market trading after the company reported better-than-e...

 why-freshpet-shares-are-trading-higher-by-around-15-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter...

 hc-wainwright--co-reiterates-buy-on-milestone-pharmaceuticals-maintains-25-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains...

 why-milestone-pharmaceuticals-mist-stock-is-rising

Milestone Pharmaceuticals shares are trading higher by 19.4% Monday morning. The company announced plans to resubmit the NDA fo...

 milestone-pharmaceuticals-plans-to-resubmit-the-nda-for-etripamil-to-fda-for-paroxysmal-supraventricular-tachycardia

Following the previously announced receipt of a Refusal to File letter, Milestone held a Type A Meeting with FDA. FDA indicated...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION